Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Etirinotecan Pegol · NKTR-102

Small molecule · Inhibitor of DNA topoisomerase I (TOP1) · developed by Nektar Therapeutics

Phase 3 Most advanced trial (none active)
NKTR Developer
5 Registered trials

What is Etirinotecan Pegol?

Etirinotecan pegol is a pegylated, extended-release form of irinotecan, a prodrug that is converted to SN38. Its active metabolite stabilizes the topoisomerase I-DNA cleavable complex, causing DNA breaks that inhibit replication and trigger apoptosis. It is studied in solid tumors, including colorectal, ovarian, lung, and breast cancers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
NKTR-102, Pegylated Irinotecan
Drug type
Small molecule
Targets
DNA topoisomerase I (TOP1)
Mechanism
Inhibitor of DNA topoisomerase I (TOP1)
Pathways
DNA replication inhibition, apoptosis
Therapy area
Oncology
Developer
Nektar Therapeutics (NKTR)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02915744 Phase 3 Metastasis Completed NKTR
NCT02312622 Phase 2 Stage IV Non-small Cell Lung Cancer (NSCLC) Completed NKTR
NCT01457118 Phase 2 Malignant Solid Tumor Completed NKTR
NCT00806156 Phase 2 Tumor Completed NKTR
NCT00598975 Phase 2 Tumor Completed NKTR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Breast CancerColorectal CancerExtensive-stage Small Cell Lung Cancer (SCLC)Malignant Solid TumorMetastasisMetastatic Breast Cancer (mBC)Ovarian CancerRecurrent Non-small Cell Lung Cancer (NSCLC)Recurrent Small Cell Lung Cancer (SCLC)Stage IV Non-small Cell Lung Cancer (NSCLC)TumorTumors Metastatic to Brain

Other drugs acting on TOP1

More from Nektar Therapeutics

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the NKTR page.

Follow NKTR, the company behind Etirinotecan Pegol

See NKTR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NKTR catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.